Clinical Trial Update: Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the combination of Brentuximab Vedotin and Nivolumab for relapsed/refractory classical Hodgkin lymphoma in patients previou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• OPDIVO (nivolumab)

Snippet

Sponsor: Emory University | Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Status: RECRUITING